Study finds potential for antidiabetic drugs to modify osteoarthritis risk

FHS
August 21, 2024
11:26 am

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

FDA develops pilot to harmonize international gene therapy regulations

The FDA is setting out to streamline international regulations of gene therapies with a pilot program to review applications alongside global regulatory partners, an agency

January 12, 2024

BICAN launches first major data release

The BRAIN Initiative® Cell Atlas Network (BICAN) has launched its first major data release, marking a significant milestone in the ambitious effort to map the

October 1, 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca’s Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is

August 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.